Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Recruiting · NCT03791034 · Observational (researchers observe without assigning treatment) · Lead sponsor: Samsung Medical Center
View the official record on ClinicalTrials.gov →What this trial is about
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
Who can take part
Age range
18 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- All subjects need to sign the informed consent form
- All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.
- Non-small cell lung cancer have to confirmed pathologically after operation
- Clinical stage I - IIIA by AJCC 7th staging system
Exclusion criteria
- Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer
- Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment
- Recurrent lung cancer
- Stage IIIB, IV by AJCC 7th staging system
Where it is running
1 location listed.
- Samsung Medical Center - Seoul, South Korea